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The value of early transmission dynamic studies in emerging 
infectious diseases
The world is braced for a public health emergency 
of international concern caused by a novel emerging 
infectious disease, a coronavirus with similarities to severe 
acute respiratory syndrome coronavirus (SARS-CoV). 
Person-to-person transmission of SARS-CoV-2, the 
causative agent of coronavirus disease 2019 (COVID-19), 
started in December, 2019, in Wuhan, China and 
has spread to become a global pandemic, with, as of 
Feb 26, 2020, community transmission in Italy, Iran, and 
South Korea.
Modelling studies have aided understanding of 
COVID-19 dynamics from the first announcement of 
the epidemic and publication of the genetic sequence 
of the causative virus. Initial phylogenetic analysis of 
closely related viruses suggested highly linked person-
to-person spread of SARS-CoV-2 originating from mid-
November to early December, 2019.1,2 Following this, 
modellers provided simple calculations that identified a 
mismatch between reported cases in China and reported 
importations of cases from travellers. Based on travel 
volumes, modellers inferred3 that cases in Wuhan were 
underestimated by a factor of 40—a crucially important 
finding. Further calculations, again based on travel 
volumes, suggested that some countries would be 
expected to have many more travel-related cases than 
had been notified,4 drawing attention to the possibility 
of undetected cases and community transmission in 
several countries.
Transmission dynamic models are a necessary first 
step in understanding the pandemic potential of an 
emerging infectious disease, including estimating 
the reproduction number—the number of new cases 
arising from a typical infected case. The first published 
transmission dynamic study of COVID-19 was rapid 
and uncomplicated, estimating the basic reproduction 
number as time-invariant5 without exploring some 
of the major underlying assumptions, such as lack of 
infectiousness during the incubation period. Since this 
early publication, many estimates for the reproduction 
rate have appeared, ranging from around 2 to more 
than 6.6
In The Lancet Infectious Diseases, the study by 
Adam Kucharski and colleagues7 addresses many of the 
assumptions of earlier works. The report contributes 
a time-varying reproduction number, showing the 
effect of the massive public health interventions put in 
place by China from Jan 23, 2020. By using additional 
datasets of travel-related exported cases, Kucharski 
and colleagues do not rely entirely on notified cases 
in Wuhan, which are likely to bias estimates caused 
by changes in case detection over time. The authors 
show that the reproduction number fell almost to the 
threshold value of 1 during the unprecedented public 
health restrictions in China.7
Kucharski and colleagues7 suggest that chains of 
transmission might not take off initially and might 
require up to four imported cases to establish 
transmission. This estimate assumes that SARS-
CoV-2 has heterogeneity of infectiousness similar to 
SARS, which was characterised by a number of super-
spreaders with most cases infecting no other people. If 
SARS-CoV-2 has a more homogenous infectiousness 
profile (to which emerging evidence is pointing) in 
which most people infect two to three others, the risk 
of established local transmission with a single imported 
case is considerably higher.
This study answers—at least in one location over 
a restricted time—a critical question regarding this 
emerging pandemic, its reproduction number.7 This 
crucial number began at 2·35 and declined to 1·05 over 
the course of December, 2019, and January, 2020. Many 
questions remain unanswered and should be addressed 
with urgency, including the infectiousness of cases over 
the duration of their illness—particularly how much 
transmission could occur from people who are unaware 
that they have illness, including asymptomatic and 
mildly symptomatic people. Initial reports suggest that 
live virus can be recovered from asymptomatic or mildly 
symptomatic people,3 which is of great concern as it 
will make disease much harder to detect and therefore 
control. However, what contribution such people 
make to the overall epidemic is unknown. Additionally, 
the infection severity, including the infection-fatality 
rate across different ages and risk groups, must be 
established. Early reports provide estimates of case 
fatality of 2·3% within China.8 However, it is notoriously 
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difficult to make such estimates early in an outbreak,9 
and it is clear that not all infections become cases and 
studies of many tiers of severity (deaths measured 
as a proportion of hospitalisations, notified cases 
and syndromic surveillance, and even potentially 
serosurveillance testing when available) will be needed 
to establish infection-fatality rates.
Ongoing modelling and surveillance should continue 
at the epicentre of the pandemic in mainland China to 
assess the effect of public health measures. However, 
attention must also move to the emerging foci outside 
of China, including Italy, Iran, and South Korea, to 
determine if the reproduction ratio might vary in 
different climates and sociological contexts. New foci 
of infection across different continents change the risk 
to global communities, as this coronavirus becomes a 
pandemic.
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Management of pregnant women infected with COVID-19
Since December, 2019, the outbreak of coronavirus 
disease 2019 (COVID-19), which originated in Wuhan, 
China, has become a global public health threat.1 On 
Feb 28, 2020, WHO upgraded their assessment of the 
risk of spread and the risk of impact of COVID-19 
to very high at global level. By March 10, 2020, 
116 166 cases have been reported globally, causing 
4088 deaths. The epidemic has spread to 118 countries 
around the world.2 
With immunocompromised status and physiological 
adaptive changes during pregnancy, pregnant women 
could be more susceptible to COVID-19 infection 
than the general population. As COVID-19 is rapidly 
spreading, maternal management and fetal safety 
become a major concern, but there is scarce information 
of assessment and management of pregnant women 
infected with COVID-19, and the potential risk of 
vertical transmission is unclear. In The Lancet Infectious 
Diseases, Nan Yu and colleagues3 report the clinical 
features and obstetric and neonatal outcomes of preg-
nancy with COVID-19 pneumonia in Wuhan, China. 
Seven pregnant women with COVID-19 pneumonia 
were assessed and the onset symptoms were similar to 
those reported in non-pregnant adults with COVID-19. 
All patients received oxygen therapy and antiviral 
treatment in isolation. All patients had caesarean 
section after consultation with a multidisciplinary team 
and the outcomes of the pregnant women and neonates 
were good. Three neonates were tested for severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), and 
one was found to be infected with COVID-19 36 h after 
birth. The findings of the study provide some indications 
for clinical assessment and management of pregnant 
women with COVID-19, but questions remain on how to 
manage pregnant women infected with COVID-19. 
As Yu and colleagues3 reported, five pregnant 
women were treated with steroids after caesarean 
section. Two were also treated with traditional Chinese 
medicine. However, no reliable evidence recommends 
any specific COVID-19 treatment for pregnant women. 
WHO guidance and some clinical evidence does not 
recommend the use of corticosteroids for COVID-19.4,5 
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